TS-000540 — A team led by Dr. Christopher Bartlett at Nationwide Children’s Hospital has developed an app to connect patients with a personalized plan created by speech therapists to aid those with a stutter. This app combines audio-visual components with text to explain an exercise, which is then recorded as the client performs it. The team expanded on this concept to include a deep neural network to provide immediate feedback, as well as the option to connect and share results on social media and with their therapist. The care provider will be able to add exercises as their patient progresses. Once an exercise is mastered, the exercise is opened permanently to the client.

TS-000433 — Flying phobia is a highly prevalent anxiety disorder, which causes sufferers significant distress and life interference. There are multiple interventions addressing flying anxiety provided through airports, commercial airlines as well as online materials. However, these services either charge fees or do not provide any aircraft/airport simulation experience. Inventors at Nationwide Children’s Hospital have designed a unique workshop curriculum which includes PowerPoint slides, a video tape and participant handouts and experimental activities. This educational intervention facilitates increasing tolerance of and comfort with air travel.

TS-000303 — Despite the high prevalence of mental health, many cases go without treatment- in part because their disorders go undiagnosed. Scientists at Nationwide Children’s Hospital have developed a computerized screening tool for behavioral health that is able to administer and score a set of mental health symptom questionnaires. This web application enables earlier identification of mental health disorders leading to earlier care.

TS-000289 — Gene therapy experts at Nationwide Children’s Hospital have made significant advancements in designing optimal viral vectors for producing Good Manufacturing Practice (GMP)-grade viral vector products. Our experts have optimized properties of vectors for a wide variety of Adeno-associated virus (AAV) serotypes, including AAV1, 2, 2.5, 3, 5, 6, 8, 9 and rh74. In particular, our experts have optimized virus packaging efficiency, reduced potential to form replication competent AAV and replaced the beta-lactam resistant gene with kanamycin in order to be compliant with European Union (EU) regulations. Our experts have made additional optimized vectors for AAVrh74, and AAV9 that allow for more efficient purification and improved CNS transduction, respectively.

TS-000278 — Background / Context / Abstract: Nearly 34 million children globally have disabling hearing loss, facing challenges in developing spoken language and literacy. Expert therapy is needed to achieve success, and no digital therapy interventions designed for deaf/hard of hearing (D/HH) children are available. Technology Overview: We have created a novel mobile app “Hear Me Read” designed to use digital storybooks as audio and video tools in therapy, in a platform that enhances family engagement for D/HH children. Therapists can select stories based on reading level, auditory and grammatical features, then assign them to parents with embedded individualized prompts and therapeutic goals. Parents can create personalized narrations of a book, explore vocabulary and the embedded therapist prompts and tasks. Our unique team is made up of pediatric hearing loss professionals (speech and language therapists, ENT surgeon), a parent of a D/HH child, and a software designer, all of whom incorporated design elements tailored to the specific learning needs of these children. Learn how “Hear Me Read” was developed to help at-risk children use storybooks in a single app to achieve multiple therapy goals over time! Benefits: The Hear Me Read platform is a modern and adaptable reading intervention tailored to the needs of D/HH children. We expect that HMR can improve spoken language and literacy outcomes in young children who are D/HH and greatly increase access to evidence-based and expert-driven therapy in those who could not otherwise attain it. We also expect to use HMR as a research tool to gain insights in literacy, accelerate and lead development of novel future reading interventions, thereby transforming therapy for D/HH (and other at risk) children. Further Details / State of Development: We have a currently functional iOS based app on an iPad platform. We have executed surveys and focus groups in speech-language pathologists and parents of D/HH children to confirm value of the product, and provide feedback on the technology (which we have incorporated). We are currently investigating the efficacy of Hear Me Read in a prospective clinical trial, which provides a unique evidence-based foundation for this technology. We are ready to move from a Minimal Viable Product to an active development phase to upgrade our software strategy, cloud-based access, and delivery model. Potential Applications / Potential Markets: We anticipate this technology to apply more broadly to children beyond D/HH, but to include other at-risk children. This may include children with: Autism Spectrum Disorder Dyslexia Specific Reading Disorder Other Reading Disorders End users may include parents of these children, as well as speech-language therapists. Teachers and schools may be secondary markets. Opportunity / Seeking: ☒Development partner ☒Commercial partner ☒Licensing ☒University spin out ☒Seeking investment We are exploring all options at this time. IP Status: ☐Patented ☒Patent application submitted ☒Provisional patent ☐No patent ☐Know-how based ☒Copyright

TS-000141 — Next Generation Sequencing (NGS) is a sequencing technology characterized by the large volume of generated DNA/RNA sequencing data. However, the cost to analyze NGS data is outstripping the cost to actually produce the data. To circumvent this challenge, the Institute for Genomics Medicine have developed a fully automated and comprehensive analysis tool called CHURCHILL. CHURCHILL’s patented novel parallelization strategy analyzes raw NGS data in a record time.